Skip to main content
OpenTrials
Completed

NCT Number: NCT05679102

Atorvastatin as an Antihypertensive Agent

This study is aimed to see the antihypertensive effect of statin (Atorvastatin) as certain animal models have shown that statins have the voltage-gated calcium channel blocking effect. It will be a randomized controlled trial that will be done in Ayub Hospital Complex Abbottabad. After ethical approval, 120 patients with newly diagnosed hypertension belonging to either gender and aged 35 and above will be enrolled in the trial. They will randomly be grouped into two groups with each group comprising 60 patients. One group will be administered Amlodipine 5 mg PO once a day, while the other one will be given 5mg Amlodipine plus 10 mg Atorvastatin. The patients will be examined on a follow-up visit 14 days later and blood pressure will be recorded as per protocols.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Atorvastatin Antihypertensive Effect

Age range

35 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Shaqra University

Shaqra, Riyadh Region, 15526, Saudi Arabia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The inclusion criteria for the study were all newly diagnosed hypertensive patients aged 35 years and above with normal lipid profile

Exclusion criteria

  • Patients with a history of dyslipidemias, diabetes mellites, chronic kidney disease, and ischemic heart disease

Treatment and study plan

Amlodipine 5 MG Oral Tablet

Drug

one group will be given only Amlodipine 5MG once daily

Amlodipine 5 MG / Atorvastatin 10 MG Oral Tablet

Drug

one group will be given Amlodipine 5mg plus Atorvastatin 10MG once daily

Primary outcomes

  1. Antihypertensive effect of atorvastatin

    Time frame: 14 days

    patients receiving atorvastatin based combination should have more decrease in the blood pressure.

Sponsors and collaborators

Lead sponsor

Himayat Ullah

Other

Collaborators

  • Ayub Teaching Hospital
  • Khyber Medical University Peshawar

Registry information

Official study title

Effect of Atorvastatin in the Management of Hypertension

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Jan 10, 2023
Registry last updated
Jan 10, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.